Targeting rare tumors: new focus for clinical research in China

Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Jiang, Yale, Miao, Huilei, Fang, Yuan, Jiang, Ning, Yu, Yue, Ma, Peiwen, Tang, Qiyu, Cui, Dandan, Fang, Hong, Huang, Huiyao, Fan, Qi, Sun, Chao, Yu, Anqi, Miao, Shuangman, Du, Jingting, Zhu, Jingxiao, Wang, Yuning, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832829/
https://www.ncbi.nlm.nih.gov/pubmed/36437781
http://dx.doi.org/10.15252/emmm.202216415
Descripción
Sumario:Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumor patients in China further provided prospects for precise and individualized targeted treatment. An ongoing phase II clinical trial, the PLATFORM study, is the first trial tailored for rare solid tumors in China, featured by molecule‐guided therapeutics. With the promulgation of supportive policies to encourage the development of innovative drugs for rare tumors in China, opportunities will be provided for these patients and the gap will be filled in the treatment of rare tumors.

Ejemplares similares